Tuesday, July 30, 2019

Expensive Gilead, Novartis Cancer Therapies Losing Patients to Experimental Treatments


By Reuters
NYT Business Day
Unusually high numbers of U.S. lymphoma patients are choosing experimental treatments over expensive cell therapies sold by Gilead Sciences Inc and Novartis AG, new data shows, helping explain why sales of the two products have not met rosy expect...
Published date: July 30, 2019 at 01:21PM
Reuters
New York Times article
By pippo at July 30, 2019
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)